Skip to main content
Caplight Logo









CatalYm

CatalYm

Private
PlaneggHealthcare & Life Scienceshttps://catalym.com

Last Round

Series D

Jul 16, 2024

Total Funding Raised

$266.04M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

CatalYm operates in Healthcare & Life Sciences and is based in Planegg. Its latest recorded funding round was a Series D round in July 2024.

CatalYm is a biopharmaceutical company that develops proprietary immunotherapies designed to overcome cancer resistance to existing oncology treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

CatalYm Comparables

Compare CatalYm with similar companies based on industry and business-model similarity.

CatalYm comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LG Chem
78%
Nanjing Leads Biolabs Co Ltd
77%
AstraZeneca
74%
Book a demo to see all comparables

For institutional investors. Book with your work email.

CatalYm Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DJul 16, 2024
Series CNov 22, 2022
Series BNov 10, 2020
SeedAug 1, 2016
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Anne Burger

CFO CEO Ad Interim, CFO

Executive Team

Scott Clarke

CEO

Executive Team

For institutional investors. Book with your work email.

CatalYm Investors

Notable investors and investment history

CatalYm investors
InvestorRounds
Forbion Capital PartnersSeries A, Series D, Series C
Omega FundsSeries D
ForbionSeries D, Series C, Series B, Series A, Seed
Gilde HealthcareSeries D
Vesalius Biocapital PartnersSeries D, Series C, Series B
Wachstumsfonds BayernSeries B
Canaan PartnersSeries D
Book a demo to see all 15 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 14, 2026

    Lead antibody visugromab advances to Phase 2b clinical studies.

  • Sep 12, 2026

    Monthly visitors increased 931% MoM, from 712 to 7.3K.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • attends_eventOct 24, 2026

    Catalym is scheduled to present updated GDFATHER-NEO clinical data and highlight ongoing Phase 2b visugromab trials at ESMO Congress 2026, which takes place Oct 23rd–27th '26 in Spain.

  • attends_eventOct 6, 2026

    Catalym attends the European Society for Medical Oncology (ESMO) Congress 2026 in Spain in Oct '26, where final GDFATHER-NEO trial results are presented in a rapid oral session and published in Nature Medicine.

Book a demo to see all news

For institutional investors. Book with your work email.

CatalYm Filings

Explore SEC and related filing metadata, where available.

CatalYm filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about CatalYm's valuation, stock price, and market status.

Is CatalYm a public or private company?

CatalYm is a private company.

What is the current stock price of CatalYm?

CatalYm is a private company, so its shares have no public market price. Caplight tracks CatalYm's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is CatalYm worth (valuation)?

Valuation information for CatalYm is not publicly available.

Can I buy CatalYm stock?

CatalYm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was CatalYm's last funding round?

CatalYm's most recent funding round was Series D on July 16, 2024.

Who are the main investors in CatalYm?

Key investors in CatalYm include Forbion Capital Partners, Vesalius Biocapital Partners, Canaan Partners, Bioqube Ventures, Jeito Capital.

Will CatalYm IPO soon?

No public IPO plans have been announced for CatalYm.

How can I track CatalYm secondary market activity?

Caplight tracks bids, offers, and trades in CatalYm's shares on secondary markets.

Firmographic Details

HeadquartersPlanegg
Employee Range50
Year Founded2016
Last FundingJul 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?